Schley Katharina, Findlow Jamie, Molina Carlos, Sullivan Shannon M, Tichy Eszter
Global Access and Value, Pfizer Pharma GmbH, 10117 Berlin, Germany.
Pfizer Global Medical Affairs, Vaccines and Antivirals, Pfizer Ltd., Tadworth KT20 7NS, UK.
Vaccines (Basel). 2025 Jun 13;13(6):642. doi: 10.3390/vaccines13060642.
The Spanish Interterritorial Council of the National Health System (a central government body) currently recommends vaccination against meningococcal serogroup C (MenC) at 4 and 12 months of age for prevention of invasive meningococcal disease (IMD). The Advisory Committee on Vaccines of the Spanish Association of Pediatrics (a professional medical association) and numerous Spanish regional bodies instead recommend quadrivalent vaccination against serogroups A, C, W, and Y (MenACWY) at 4 and 12 months of age. The central government and Spanish Association of Pediatrics also recommend MenACWY vaccination at 12 years of age. This study assessed the potential public health effects of replacing the MenC vaccination schedule with different MenACWY vaccination schedules in infants. Here, a static multi-cohort population model was used to evaluate potential effects on public health of IMD due to meningococcal serogroups C/W/Y, comparing MenC infant vaccination (reference strategy) against four different strategies including quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix, Pfizer Europe MA EEIG, Brussels, Belgium) infant vaccination; all strategies included MenACWY-TT vaccination at 12 years of age. The most effective strategy for infant vaccination was MenACWY-TT at 2, 4, and 12 months, preventing an estimated additional 103 IMD cases, 17 deaths, and 41 cases with long-term sequelae (LTS) versus the reference strategy in the base-case IMD incidence scenario. When strategies included a two-dose infant schedule, the earlier the infant MenACWY-TT vaccine was administered, the more additional cases, deaths, and cases with LTS were prevented (base-case and high-incidence scenarios). This analysis supports implementation of MenACWY-TT as a replacement for MenC vaccination.
西班牙国家卫生系统跨地区委员会（一个中央政府机构）目前建议在4个月和12个月大时接种C群脑膜炎球菌（MenC）疫苗，以预防侵袭性脑膜炎球菌病（IMD）。而西班牙儿科学会疫苗咨询委员会（一个专业医学协会）以及众多西班牙地区机构则建议在4个月和12个月大时接种A、C、W和Y群四价疫苗（MenACWY）。中央政府和西班牙儿科学会还建议在12岁时接种MenACWY疫苗。本研究评估了在婴儿中用不同的MenACWY疫苗接种方案替代MenC疫苗接种方案可能对公共卫生产生的影响。在此，使用了一个静态多队列人群模型来评估C/W/Y群脑膜炎球菌引起的IMD对公共卫生的潜在影响，将婴儿接种MenC疫苗（参考策略）与四种不同策略进行比较，包括接种四价破伤风类毒素结合疫苗（MenACWY-TT；Nimenrix，辉瑞欧洲MA EEIG，比利时布鲁塞尔）；所有策略均包括在12岁时接种MenACWY-TT疫苗。婴儿接种的最有效策略是在2个月、4个月和12个月时接种MenACWY-TT，与基础病例IMD发病率情景下的参考策略相比，估计可额外预防103例IMD病例、17例死亡和41例有长期后遗症（LTS）的病例。当策略包括两剂婴儿接种方案时，婴儿MenACWY-TT疫苗接种越早，预防的额外病例、死亡和LTS病例就越多（基础病例和高发病率情景）。该分析支持实施MenACWY-TT替代MenC疫苗接种。
